Cancer Treatment Centers of America® Puts Precision Cancer Treatment at the Forefront of Care Through the Use of Advanced Genomic Testing

BOCA RATON, Fla., May 5, 2015 /PRNewswire/ -- Cancer Treatment Centers of America^® Global (CTCA) today unveiled its new Centers for Advanced Individual Medicine, a resource that will make advanced genomic testing available to clinically qualified patients recommended by their physicians. The CTCA hospital-based Centers will provide patients and physicians with access to advanced genomic testing when recommended by a patient's physician, and help educate patients about the potential benefits of precision cancer treatment.

Precision cancer treatment using advanced genomic testing is an emerging diagnostic tool that enables physicians to evaluate possible treatment options that may not have been considered previously. Through the identification of the root genetic abnormality within a patient's cancer, physicians may be able to prescribe more individualized and targeted treatment options.

The Centers will have designated specialists – including oncology-certified nurses and patient care coordinators – onsite to help educate patients and their families, while also helping physicians with patient counseling and guidance throughout the testing process.   

"Knowledge is truly power when it comes to cancer treatment, and we are committed to providing our patients with every possible tool to help fight their cancer," said Maurie Markman, MD, President of Medicine and Science at CTCA. "Advanced genomic testing is a critical tool for today's physicians, and I'm proud that we're able to offer this resource to support and empower our care teams to help define a more customized treatment approach for our patients."

Advanced genomic testing is not appropriate or recommended for every cancer patient. It is intended primarily for patients for whom standard of care did not produce favorable results, no longer produces desired results or does not exist, and the patient may benefit from targeted therapies not considered previously.

Genomic testing currently is considered "routine care" for a limited number of cancers, including breast and lung cancers. "As advanced genomic testing continues to evolve, it is critical that physicians and patient care teams are given these advanced resources to help them stay at the forefront of this very promising field of medicine," added Markman.

More information about precision medicine can be found on the CTCA website: www.cancercenter.com.

About Cancer Treatment Centers of America^®
Cancer Treatment Centers of America Global (CTCA), with headquarters in Boca Raton, Fla., is a national network of five hospitals that specialize in the treatment of patients fighting complex or advanced-stage cancer. CTCA offers an integrative approach to cancer treatment that combines surgery, radiation, and chemotherapy with nutritional counseling, naturopathic medicine, mind-body therapy, and spiritual support to enhance quality of life and minimize side effects during treatment. The company serves patients from around the world at hospitals located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Standard^® of care and Patient Empowerment Medicine^®, CTCA provides patients with comprehensive information about their treatment options so they can participate in their treatment decisions. For more information about CTCA, go to www.cancercenter.com, facebook.com/CancerCenter and twitter.com/CancerCenter.

Contact:
Ellen Crane
[email protected]
(561) 923-3149

SOURCE Cancer Treatment Centers of America

Related Links

http://www.cancercenter.com